Pilot study of the effect of the simvastatin-ciprofibrate combination on myocardial infarction risk profile in patients with refractory familial combined hyperlipidaemia

Clinical Drug Investigation

Volumn 11, Issue 4, 1996, Pages 196-204

  Athyros, Vasilios G ^a,b   Papageorgiou, Athanasios A ^a   Basagiannis, Elias C ^a   Lafaras, Christos T ^a   Kontopoulos, Athanasios G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CIPROFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DRUG EFFECT; DRUG EFFICACY; FAMILIAL HYPERLIPEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HUMAN; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROBABILITY; RISK; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029871062     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199611040-00002     Document Type: Article

References (43)

1. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia work-shop. Arteriosclerosis 1987; 79 (2): 203-7
2. Krauss RM. Dense low-density lipoproteins and coronary artery disease. Am J Cardiol 1995; 75 (6 Suppl.): B53-B57
3. Franceschini G, Cassinotti M, Vecchio G, et al. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidaemia without changing LDL subclass pattern. Arterioscler Thromb 1994; 14 (10): 1569-75
4. Dejager S, Bruckert E, Chapman MJ. Dense low-density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34 (2): 295-308
5. Thomson GR. A handbook of hyperlipidaemia. London: Current Science, 1990: 129-41
6. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988; 109 (1): 25-32
7. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5
8. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94 (1): 13-20
9. Athyros V, Papageorgiou A, Hagikonstantinou H, et al. Combined treatment with pravastatin and gemfibrozil in patients with refractory familial combined hyperlipidaemia. Drug Invest 1994; 7 (3): 134-42
10. Lintott CJ, Scott RS, Nye ER, et al. The hypolipidaemic effects of pravastatin alone and in combination with bezafibrate or acipimox in patients with primary hypercholesterolaemia. Diab Nutr Metab 1991; 4 (1): 1-6
11. Yeshurun D, Abukarshin R, Elias N, et al. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. Clin Ther 1993; 15: 335-63
12. The Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
13. Gaw A, Packard CJ, Caslake MJ, et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994; 108 (2): 137-48
14. Oro L, Carson LA, Olsson A, et al. Long term effect of ciprofibrate in patients with primary hyperlipidemia. Curr Ther Res 1992; 51 (2): 229-43
15. Athyros V, Papageorgiou A, Avramides M, et al. Effect of pravastatin on coronary heart disease prevention in patients with primary hypercholesterolemia. Curr Ther Res 1994; 55 (8): 914-24
16. Athyros V, Papageorgiou A, Avramides M, et al. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidemia. Coron Artery Dis 1995; 6 (3): 251-6
17. Kontopoulos A, Athyros V, Papageorgiou A, et al. Effect of sustained hyperinsulinemia on coronary heart disease risk factors in salt-sensitive essential hypertensives. High Blood Press Cardiovasc Prev 1995; 4: 129-36
18. Papageorgiou A, Athyros V, Avramidis M, et al. A computer program (TYPMI) co-evaluating ten independent coronary heart disease risk factors. Greek Med 1993; 59 (1): 115-23
19. Austin MA, Brunzell JD, Fitch WL, et al. Inheritance of low-density lipoprotein subclass pattern in familial combined hyperlipoproteinaernia. Arteriosclerosis 1990; 10 (5): 520-30
20. Hokanson JE, Austin MA, Zambon A, et al. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1993; 13 (3): 427-34
21. Bredie SJ, de Bruin TW, Demacker PN, et al. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995; 75 (4): 348-53
22. Griffin BA, Caslake MJ, Gaw A, et al. Effects of cholestyramine and acipimox on subfractions of plasma LDL. Studies in normolipidaemic and hypercholesterolaemic subjects. Eur J Clin Invest 1992; 22: 383-90
23. Austin MA, Krauss RM. Genetic control of low-density-lipoprotein subclasses. Lancet 1986; 11 (8507): 592-5
24. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82 (2): 495-506
25. Grundy SM. Drug therapy: HMG CoA reduclase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24-32
26. Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106 (2): 241-53
27. Watson TD, Caslake MJ, Freeman DJ, et al. Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. Arterioscler Thromb 1994; 14 (6): 902-10
28. Shepherd J. Mechanism of action of fibrates. Postgrad Med J 1993; 69 Suppl. 1: 34-41
29. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993; 100 (1): 91-102
30. Homma Y, Ozawu H, Kobayashi T, et al. Effects of bezalibrate therapy on subtractions of plasma LDL and HDL, and on the activities of LCAT and CETP in patients with hyperlipoproteinemia. Atherosclerosis 1994; 106 (20): 191-201
31. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993; 13 (5): 702-11
32. Assmann G, Schulte H. Relation of high-density lipoprotein and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70 (7): 733-7
33. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Arch Intern Med 1992; 152: 28-34
34. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (two parts). N Engl J Med 1992; 326: 242-50, 310-8
35. Simson IA, Lorimer AR, Walker ID, et al. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolemia. Thromb Haemost 1985; 54: 442-4
36. Kwiterovich PO Jr, Coresh J, Smith HH, et al. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol 1992; 69 (12): 1015-21
37. Barbi G, Corder CN, Koren E, et al. Effect of pravastatin and cholestyramine on triglyceride-rich lipoprotein particles and Lp(a) in patients with type II hypercholesterolemia. Drug Dev Res 1992; 27: 297-306
38. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62 (15): J28-J34
39. Willis RA, Folkers K, Tucker JL, et al. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990; 87: 8928-30
40. Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993; 46: 1055-7
41. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-lerm simvastatin treatment in humans. Clin Pharmacol Ther 1995; 57 (1): 62-6
42. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85 (1): 37-45
43. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333 (20): 1301-7